JENS PEDERSEN-BJERGAARD, M.D.; JENS ERSBØLL, M.D.; HILDA MYGIND SØRENSEN, M.D.; NIELS KEIDING, M.Sc.; SEVERIN OLESEN LARSEN, M.Sc.; PREBEN PHILIP, M.D.; MOGENS SALLING LARSEN, M.D.; HENRIK SCHULTZ, M.D.; NIS I. NISSEN, M.D.
PEDERSEN-BJERGAARD J, ERSBØLL J, SØRENSEN HM, KEIDING N, LARSEN SO, PHILIP P, et al. Risk of Acute Nonlymphocytic Leukemia and Preleukemia in Patients Treated with Cyclophosphamide for Non-Hodgkin's Lymphomas: Comparison with Results Obtained in Patients Treated for Hodgkin's Disease and Ovarian Carcinoma with Other Alkylating Agents. Ann Intern Med. 1985;103:195-200. doi: 10.7326/0003-4819-103-2-195
Download citation file:
Published: Ann Intern Med. 1985;103(2):195-200.
Of 602 patients treated for non-Hodgkin's lymphomas, 9 developed overt acute nonlymphocytic leukemia or preleukemia with refractory cytopenia and cytogenetic abnormalities of the bone marrow. A Kaplan-Meier estimate of the cumulative probability of leukemic complications was 6.3 ± 2.6% (mean ± SE) 7 years after start of treatment. All 9 patients with leukemic complications belong to a major subgroup of 498 patients treated with alkylating agents, predominantly cyclophosphamide. The risk of leukemic complications in this subgroup was compared with the risk in 312 patients treated with other alkylating agents for Hodgkin's disease, and with the risk in 553 patients treated with dihydroxybusulfan for ovarian carcinoma. Cumulative 9-year risks were 8.0 ± 3.3%, 12.8 ± 3.5%, and 7.1 ± 1.9%, respectively. The general risk of secondary leukemia after long-term treatment with alkylating agents ranges from 1% to 1.5% per year from 2 to at least 9 years after start of treatment.
Learn more about subscription options.
Register Now for a free account.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only